CytRx to add oral vaccine technology through Zynaxis acquisition; Medarex to acquire Houston Bio.
Executive Summary
CYTRx ADDING ORAL VACCINE TECHNOLOGY TO PORTFOLIO THROUGH ZYNAXIS, which will be merged into CytRx' Vaxcel injectable vaccines subsidiary, the company announced Dec. 6. The deal, expected to close in March or early April, will enable Vaxcel to go public with former Zynaxis shareholders owning 12.5% of the company.